Michele Maffezzoli

ORCID

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 14

Top Venues

Clinical & experimental metastasis

Future oncology (London, England)

Immunotherapy

This page only lists publications with an associated author ORCID identifier.

Publications

Michele Maffezzoli, Matteo Santoni, Giulia Mazzaschi, Sara Rodella, Eleonora Lai, Marco Maruzzo, Umberto Basso, Davide Bimbatti, Roberto Iacovelli, Annunziato Anghelone, Ondřej Fiala, Sara Elena Rebuzzi, Giuseppe Fornarini, Cristian Lolli, Francesco Massari, Matteo Rosellini, Veronica Mollica, Cecilia Nasso, Alessandro Acunzo, Enrico Maria Silini, Federico Quaini, Massimo De Filippo, Matteo Brunelli, Giuseppe L Banna, Pasquale Rescigno, Alessio Signori, Sebastiano Buti
External validation of a red cell-based blood prognostic score in patients with metastatic renal cell carcinoma treated with first-line immunotherapy combinations. Clinical & experimental metastasis 41 (2) (2024)
Michele Maffezzoli, Matteo Santoni, Giulia Mazzaschi, Sara Rodella, Eleonora Lai, Marco Maruzzo, Umberto Basso, Davide Bimbatti, Roberto Iacovelli, Annunziato Anghelone, Ondřej Fiala, Sara Elena Rebuzzi, Giuseppe Fornarini, Cristian Lolli, Francesco Massari, Matteo Rosellini, Veronica Mollica, Cecilia Nasso, Alessandro Acunzo, Enrico Maria Silini, Federico Quaini, Massimo De Filippo, Matteo Brunelli, Giuseppe L Banna, Pasquale Rescigno, Alessio Signori, Sebastiano Buti
External validation of a red cell-based blood prognostic score in patients with metastatic renal cell carcinoma treated with first-line immunotherapy combinations. Clinical & experimental metastasis (2024)
Fabio Catalano, Matteo Brunelli, Alessio Signori, Pasquale Rescigno, Sebastiano Buti, Luca Galli, Massimiliano Spada, Cristina Masini, Francesca Galuppini, Valerio Gaetano Vellone, Gabriele Gaggero, Maruzzo Marco, Sara Merler, Francesca Vignani, Alessia Cavo, Davide Bimbatti, Michele Milella, Angelo Paolo Dei Tos, Marta Sbaraglia, Veronica Murianni, Alessandra Damassi, Malvina Cremante, Michele Maffezzoli, Miguel Angel Llaja Obispo, Giuseppe Luigi Banna, Giuseppe Fornarini, Sara Elena Rebuzzi
Analyses of tumor microenvironment in patients with advanced renal cell carcinoma receiving immunotherapy (Meet-URO 18 study). Future oncology (London, England) (2024)
Michele Maffezzoli, Matteo Santoni, Giulia Mazzaschi, Sara Rodella, Eleonora Lai, Marco Maruzzo, Umberto Basso, Davide Bimbatti, Roberto Iacovelli, Annunziato Anghelone, Ondřej Fiala, Sara Elena Rebuzzi, Giuseppe Fornarini, Cristian Lolli, Francesco Massari, Matteo Rosellini, Veronica Mollica, Cecilia Nasso, Alessandro Acunzo, Enrico Maria Silini, Federico Quaini, Massimo De Filippo, Matteo Brunelli, Giuseppe L Banna, Pasquale Rescigno, Alessio Signori, Sebastiano Buti
External validation of a red cell-based blood prognostic score in patients with metastatic renal cell carcinoma treated with first-line immunotherapy combinations. Clinical & experimental metastasis 41 (2) (2024)
Michele Maffezzoli, Sebastiano Buti
Prognostication for surgically treated papillary renalcell carcinoma: which model is the optimal choice? Future oncology (London, England) (2024)
Fabio Catalano, Matteo Brunelli, Alessio Signori, Pasquale Rescigno, Sebastiano Buti, Luca Galli, Massimiliano Spada, Cristina Masini, Francesca Galuppini, Valerio Gaetano Vellone, Gabriele Gaggero, Maruzzo Marco, Sara Merler, Francesca Vignani, Alessia Cavo, Davide Bimbatti, Michele Milella, Angelo Paolo Dei Tos, Marta Sbaraglia, Veronica Murianni, Alessandra Damassi, Malvina Cremante, Michele Maffezzoli, Miguel Angel Llaja Obispo, Giuseppe Luigi Banna, Giuseppe Fornarini, Sara Elena Rebuzzi
Analyses of tumor microenvironment in patients with advanced renal cell carcinoma receiving immunotherapy (Meet-URO 18 study). Future oncology (London, England) (2024)
Fabiana Perrone, Federica Pecci, Michele Maffezzoli, Giulia Claire Giudice, Valeria Cognigni, Giulia Mazzaschi, Luca Cantini, Luca Santamaria, Francesco Paoloni, Marco Luigi Bruno Rocchi, Matilde Coriano', Alessandro Acunzo, Federico Quaini, Marcello Tiseo, Saini S Kamal, Rossana Berardi, Sebastiano Buti
Differential impact of lipid profile according to neutrophil-to-lymphocyte ratio status in patients with advanced cancer treated with immunotherapy. Immunotherapy (2024)
Michele Maffezzoli, Matteo Santoni, Giulia Mazzaschi, Sara Rodella, Eleonora Lai, Marco Maruzzo, Umberto Basso, Davide Bimbatti, Roberto Iacovelli, Annunziato Anghelone, Ondřej Fiala, Sara Elena Rebuzzi, Giuseppe Fornarini, Cristian Lolli, Francesco Massari, Matteo Rosellini, Veronica Mollica, Cecilia Nasso, Alessandro Acunzo, Enrico Maria Silini, Federico Quaini, Massimo De Filippo, Matteo Brunelli, Giuseppe L Banna, Pasquale Rescigno, Alessio Signori, Sebastiano Buti
External validation of a red cell-based blood prognostic score in patients with metastatic renal cell carcinoma treated with first-line immunotherapy combinations. Clinical & experimental metastasis 41 (2) (2024)
Michele Maffezzoli, Matteo Santoni, Giulia Mazzaschi, Sara Rodella, Eleonora Lai, Marco Maruzzo, Umberto Basso, Davide Bimbatti, Roberto Iacovelli, Annunziato Anghelone, Ondřej Fiala, Sara Elena Rebuzzi, Giuseppe Fornarini, Cristian Lolli, Francesco Massari, Matteo Rosellini, Veronica Mollica, Cecilia Nasso, Alessandro Acunzo, Enrico Maria Silini, Federico Quaini, Massimo De Filippo, Matteo Brunelli, Giuseppe L Banna, Pasquale Rescigno, Alessio Signori, Sebastiano Buti
External validation of a red cell-based blood prognostic score in patients with metastatic renal cell carcinoma treated with first-line immunotherapy combinations. Clinical & experimental metastasis 41 (2) (2024)
Michele Maffezzoli, Matteo Santoni, Giulia Mazzaschi, Sara Rodella, Eleonora Lai, Marco Maruzzo, Umberto Basso, Davide Bimbatti, Roberto Iacovelli, Annunziato Anghelone, Ondřej Fiala, Sara Elena Rebuzzi, Giuseppe Fornarini, Cristian Lolli, Francesco Massari, Matteo Rosellini, Veronica Mollica, Cecilia Nasso, Alessandro Acunzo, Enrico Maria Silini, Federico Quaini, Massimo De Filippo, Matteo Brunelli, Giuseppe L Banna, Pasquale Rescigno, Alessio Signori, Sebastiano Buti
External validation of a red cell-based blood prognostic score in patients with metastatic renal cell carcinoma treated with first-line immunotherapy combinations. Clinical & experimental metastasis 41 (2) (2024)
Fabio Catalano, Matteo Brunelli, Alessio Signori, Pasquale Rescigno, Sebastiano Buti, Luca Galli, Massimiliano Spada, Cristina Masini, Francesca Galuppini, Valerio Gaetano Vellone, Gabriele Gaggero, Maruzzo Marco, Sara Merler, Francesca Vignani, Alessia Cavo, Davide Bimbatti, Michele Milella, Angelo Paolo Dei Tos, Marta Sbaraglia, Veronica Murianni, Alessandra Damassi, Malvina Cremante, Michele Maffezzoli, Miguel Angel Llaja Obispo, Giuseppe Luigi Banna, Giuseppe Fornarini, Sara Elena Rebuzzi
Analyses of tumor microenvironment in patients with advanced renal cell carcinoma receiving immunotherapy (Meet-URO 18 study). Future oncology (London, England) (2024)
Michele Maffezzoli, Sebastiano Buti
Prognostication for surgically treated papillary renal cell carcinoma: which model is the optimal choice? Future oncology (London, England) 20 (3) (2024)
Michele Maffezzoli, Sebastiano Buti
Prognostication for surgically treated papillary renal cell carcinoma: which model is the optimal choice? Future oncology (London, England) 20 (3) (2024)
Giulia Airò, Michele Maffezzoli, Alessandro Lazzarin, Michele Bianconcini, Alessandro Greco, Sebastiano Buti, Alessandro Leonetti
Takotsubo syndrome in a patient with metastatic renal cell carcinoma treated with pembrolizumab plus axitinib. Immunotherapy 14 (16) (2022)

Michele Maffezzoli.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Michele Maffezzoli